Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists.

Stein A, Markus M, Jörg T, Eray G, Vogel A.

Crit Rev Oncol Hematol. 2018 Oct;130:13-26. doi: 10.1016/j.critrevonc.2018.07.001. Epub 2018 Jul 11. Review.

PMID:
30196908
2.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.

Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators.

Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4.

PMID:
29880231
3.

T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker.

Akyüz N, Brandt A, Stein A, Schliffke S, Mährle T, Quidde J, Goekkurt E, Loges S, Haalck T, Ford CT, Asemissen AM, Thiele B, Radloff J, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Binder M.

Int J Cancer. 2017 Jun 1;140(11):2535-2544. doi: 10.1002/ijc.30549. Epub 2017 Mar 6.

4.

Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.

Kaifie A, Isfort S, Gattermann N, Hollburg W, Klausmann M, Wolf D, Maintz C, Hänel M, Goekkurt E, Göthert JR, Platzbecker U, Geer T, Parmentier S, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL).

Ann Hematol. 2016 Sep;95(9):1399-410. doi: 10.1007/s00277-016-2730-y. Epub 2016 Jun 22.

PMID:
27334946
5.

γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm.

Görtzen J, Hunka LM, Vonnahme M, Praktiknjo M, Kaifie A, Fimmers R, Jansen C, Heine A, Lehmann J, Goethert JR, Gattermann N, Goekkurt E, Platzbecker U, Brossart P, Strassburg CP, Brummendorf TH, Koschmieder S, Wolf D, Trebicka J.

Medicine (Baltimore). 2016 May;95(20):e3355. doi: 10.1097/MD.0000000000003355.

6.

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).

Vansteenkiste J, Barlesi F, Waller CF, Bennouna J, Gridelli C, Goekkurt E, Verhoeven D, Szczesna A, Feurer M, Milanowski J, Germonpre P, Lena H, Atanackovic D, Krzakowski M, Hicking C, Straub J, Picard M, Schuette W, O'Byrne K.

Ann Oncol. 2015 Aug;26(8):1734-40. doi: 10.1093/annonc/mdv219. Epub 2015 May 4.

PMID:
25939894
7.

Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity.

Harbaum L, Marx A, Goekkurt E, Schafhausen P, Atanackovic D.

Int J Hematol. 2014 Jan;99(1):91-4. doi: 10.1007/s12185-013-1474-x. Epub 2013 Nov 22.

PMID:
24264834
8.

A genomics-based classification of human lung tumors.

Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM).

Sci Transl Med. 2013 Oct 30;5(209):209ra153. doi: 10.1126/scitranslmed.3006802.

9.

Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Stenholm L, Stoehlmacher-Williams J, Al-Batran SE, Heussen N, Akin S, Pauligk C, Lehmann S, Senff T, Hofheinz RD, Ehninger G, Kramer M, Goekkurt E.

Ann Oncol. 2013 Oct;24(10):2581-8. doi: 10.1093/annonc/mdt330. Epub 2013 Aug 23.

PMID:
23975664
10.

EGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinoma.

Hoffmann AC, Goekkurt E, Danenberg PV, Lehmann S, Ehninger G, Aust DE, Stoehlmacher-Williams J.

PLoS One. 2013 May 21;8(5):e64186. doi: 10.1371/journal.pone.0064186. Print 2013.

11.

Cytogenetics of extramedullary manifestations in multiple myeloma.

Billecke L, Murga Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, Schiby G, Kröger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Heidtmann HH, Vettorazzi E, Dierlamm J, Bokemeyer C, Schilling G.

Br J Haematol. 2013 Apr;161(1):87-94. doi: 10.1111/bjh.12223. Epub 2013 Feb 1.

PMID:
23368088
12.

Similar incidences of TP53 deletions in extramedullary organ infiltrations, soft tissue and osteolyses of patients with multiple myeloma.

Billecke L, Penas EM, May AM, Engelhardt M, Nagler A, Leiba M, Schiby G, Kröger N, Zustin J, Marx A, Matschke J, Tiemann M, Goekkurt E, Bokemeyer C, Schilling G.

Anticancer Res. 2012 May;32(5):2031-4.

PMID:
22593484
13.

Polymorphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC).

Stoehlmacher-Williams J, Obermann L, Ehninger G, Goekkurt E.

Anticancer Res. 2012 Feb;32(2):421-5.

PMID:
22287728
14.

Molecular analysis of the polymorphisms of thymidylate synthase on cell-free circulating DNA in blood of patients with advanced colorectal carcinoma.

Schwarzenbach H, Goekkurt E, Pantel K, Aust DE, Stoehlmacher J.

Int J Cancer. 2010 Aug 15;127(4):881-8. doi: 10.1002/ijc.25096.

15.

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.

Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH.

Lancet Oncol. 2010 Jan;11(1):38-47. doi: 10.1016/S1470-2045(09)70330-4. Epub 2009 Nov 26.

PMID:
19942479
16.

The EGFR pathway as an example for genotype: phenotype correlation in tumor genes.

Mogck U, Goekkurt E, Stoehlmacher J.

Methods Mol Biol. 2010;576:341-50. doi: 10.1007/978-1-59745-545-9_17.

PMID:
19882270
17.

Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.

Goekkurt E, Al-Batran SE, Hartmann JT, Mogck U, Schuch G, Kramer M, Jaeger E, Bokemeyer C, Ehninger G, Stoehlmacher J.

J Clin Oncol. 2009 Jun 10;27(17):2863-73. doi: 10.1200/JCO.2008.19.1718. Epub 2009 Mar 30.

PMID:
19332728
18.

Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.

Platzbecker U, von Bonin M, Goekkurt E, Radke J, Binder M, Kiani A, Stoehlmacher J, Schetelig J, Thiede C, Ehninger G, Bornhäuser M.

Biol Blood Marrow Transplant. 2009 Jan;15(1):101-8. doi: 10.1016/j.bbmt.2008.11.004.

19.

Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Goekkurt E, Al-Batran SE, Mogck U, Pauligk C, Hartmann JT, Kramer M, Jaeger E, Ehninger G, Stoehlmacher J.

Ann Oncol. 2009 Mar;20(3):481-5. doi: 10.1093/annonc/mdn667. Epub 2008 Dec 12.

PMID:
19074750
20.

Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer.

Schwarzenbach H, Stoehlmacher J, Pantel K, Goekkurt E.

Ann N Y Acad Sci. 2008 Aug;1137:190-6. doi: 10.1196/annals.1448.025.

PMID:
18837946

Supplemental Content

Loading ...
Support Center